Hormone-free option
Safety focused
Women’s Health Clinic FAQ
Do intimate polynucleotides improve sexual sensation?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
Intimate polynucleotides should not be promised as a sexual-sensation or arousal treatment. They may improve comfort in selected patients if dryness, tissue fragility or painful friction is affecting intimacy, but sexual response is multifactorial. Nerve sensitivity, pelvic-floor tone, hormones, medication, pain history, relationship context and psychological factors can all matter. The aim should be better tissue comfort and confidence where appropriate, not a promised improvement in desire, orgasm or sensation.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Mechanism
Uses highly purified DNA fragments (typically derived from salmon or trout) to trigger cellular regeneration, angiogenesis, and deep tissue hydration.
Indications
Treats symptoms of Genitourinary Syndrome of Menopause (GSM) and vulvovaginal atrophy (VVA), including dryness, burning, itching, and tissue laxity.
Synergistic Formulas
Frequently combined with Hyaluronic Acid (HA) and mannitol (e.g., NewGyn®) to provide immediate moisture while polynucleotides rebuild tissue over time.
Hormone-Free
A non-surgical, non-hormonal approach ideal for patients who cannot or prefer not to use ooooestrogen therapy.
Important safety note
Safety Profile: Polynucleotides are extremely biocompatible, lacking active proteins, thus presenting an exceptionally low risk of immunogenic or allergic reactions.
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
Sensation is multifactorial
Sexual response involves tissue comfort, nerves, pelvic-floor tone, hormones, pain history and context.
Avoid sexual enhancement claims
PN may support comfort where dryness or fragility is relevant, but it should not promise arousal or orgasm change.
Evidence
Symptoms
Alternatives
What it means
Efficacy in Atrophy: An exploratory study using an injectable PN and HA combination demonstrated a 59.4% reduction in dyspareunia and a 59.1% reduction in vaginal dryness scores after 90 days.
Why symptoms matter
Topical Ovule Success: A real-world trial of postmenopausal women using PN-based vaginal ovules showed a 59.8% improvement in vaginal hydration and a 50.9% improvement in tissue elasticity.
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
Setting & Duration: The procedure is performed in an outpatient clinical setting and usually takes 10 to 45 minutes depending on the targeted areas.
What this means in practice
Setting & Duration: The procedure is performed in an outpatient clinical setting and usually takes 10 to 45 minutes depending on the targeted areas.
Initial Sessions: A typical treatment course requires 3 to 5 sessions, usually spaced 2 to 4 weeks apart.
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Efficacy in Atrophy: An exploratory study using an injectable PN and HA combination demonstrated a 59.4% reduction in dyspareunia and a 59.1% reduction in.
It protects safety
Safety Profile: Polynucleotides are extremely biocompatible, lacking active proteins, thus presenting an exceptionally low risk of immunogenic or allergic reactions.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Consultation: The journey begins with a thorough medical assessment to evaluate symptoms of VVA/GSM, review medical history, and rule out any contraindications.
During care
Preparation: Patients are advised to abstain from alcohol, smoking, and blood-thinning medications (like NSAIDs or fish oils) for 24-48 hours prior to minimise bruising.
Aftercare
Treatment Day: After cleansing and numbing, the clinician administers the polynucleotide solution. The injections cause minimal discomfort.
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Initial Sessions: A typical treatment course requires 3 to 5 sessions, usually spaced 2 to 4 weeks apart.
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments used for gradual tissue-quality support, not instant volume.
Myth: hormone-free means suitable for everyone
Reality: fish allergy, infection, bleeding, pregnancy, recent surgery and unclear pain can make treatment unsuitable.
Myth: results are promised
Reality: response varies and should be reviewed before repeating treatment.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
PubMed: PN/HA intradermal treatment for vulvovaginal atrophy
This pilot study is directly relevant to PN/HA use in vulvovaginal atrophy and supports cautious evidence-aware discussion.
NICE menopause recommendations
NICE provides UK guidance for GSM, vaginal ooestrogen, non-hormonal care and cancer-history decision-making.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 59 imported records. Additional reviewed material included peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
